| Artin Shahbazian, PHARMD | |
|
5747 Kanan Rd, Agoura Hills, CA 91301-1601 | |
| (818) 991-5258 | |
| Not Available |
| Full Name | Artin Shahbazian |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 5747 Kanan Rd, Agoura Hills, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1891163705 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 73246 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Artin Shahbazian, PHARMD 5747 Kanan Rd, Agoura Hills, CA 91301-1601 Ph: (818) 991-5258 | Artin Shahbazian, PHARMD 5747 Kanan Rd, Agoura Hills, CA 91301-1601 Ph: (818) 991-5258 |
News Archive
Girls treated for Hodgkin's disease during adolescence acquire a considerable risk of developing breast cancer, as shown by an observational study published in the current issue of Deutsches Ärzteblatt International.
New York University chemists have developed a computational approach for determining the viability and suitability of complex molecular structures—an advancement that could aid in the development of pharmaceuticals as well as a range of other materials.
Pieces in the complex autism inheritance puzzle are emerging in the latest study from a research team including geneticists from the University of Pennsylvania School of Medicine and The Children's Hospital of Philadelphia (CHOP). The study identified 27 different genetic regions where rare copy number variations - missing or extra copies of DNA segments - were found in the genes of children with autism spectrum disorders, but not in the healthy controls. The findings are published June 26 in the open-access journal PLoS Genetics.
Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced the dosing of the first patient under the Company's recently initiated Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients. The study will evaluate the localization, safety, tolerability and preliminary treatment response of SL052 photodynamic therapy in 18 patients with localized prostate cancer.
› Verified 7 days ago
Mr. Philip L Berger, BPHARM Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 30495 Canwood St, Agoura Hills, CA 91301 Phone: 818-532-7150 | |
Cindy Trish Mai, PHARM. D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 5747 Kanan Rd, Agoura Hills, CA 91301 Phone: 818-991-5258 | |
Mrs. Helen Saulsberry, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 5623 Kanan Rd, Agoura Hills, CA 91301 Phone: 818-991-5522 Fax: 818-707-1038 | |
John Ingram Vaile, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 29140 Medea Ln, Apt 1114, Agoura Hills, CA 91301 Phone: 201-638-4315 | |
Sandra Day Morales Agustin, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 27804 Via Amistosa, Agoura Hills, CA 91301 Phone: 818-970-6928 | |
Neda Kalali, PHARM.D., MHSA Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 28945 Oak Creek Ln Apt 2104, Agoura Hills, CA 91301 Phone: 818-307-0972 | |
Abanob Anis, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 5747 Kanan Rd, Agoura Hills, CA 91301 Phone: 818-991-5258 Fax: 818-991-3916 |